Ara-290
Erythropoietin-derived peptide (ARA-290). Innate-repair receptor-binding research.
Specification
- Catalogue ID: SP101
- Listed purity specification: 99.5%
- Formulation: Lyophilized
- Quantity: 10mg / Vial
- Price: £75.00
Innate-repair receptor research · EPO-derived peptide pharmacology
Ara-290 (cibinetide) is an 11-amino-acid synthetic peptide derived from the helix-B surface peptide (HBSP) region of erythropoietin (EPO). Unlike EPO itself, Ara-290 is engineered to bind the tissue-protective, non-haematopoietic receptor subtype — the innate repair receptor (IRR), a heteromeric complex involving the β-common receptor (βcR) — rather than the classical EPO receptor homodimer responsible for erythropoiesis.
In vitro, the compound has been studied for its interactions with the IRR and for effects on downstream signalling pathways including JAK2/STAT3 and PI3K/Akt, which are implicated in cytoprotective and anti-apoptotic responses in neuronal and pancreatic β-cell culture models.
Ara-290 is used as a tool compound in research exploring the dissociation of EPO's haematopoietic and non-haematopoietic receptor pharmacology — a topic of growing interest in neuroprotection and metabolic-disease in-vitro research.
No physiological or therapeutic properties are claimed; supplied for in-vitro laboratory research use only.
Compound identity
- CAS number: 944008-46-2
- Molecular formula: C₂₁H₃₃N₅O₈S
- Molecular weight: 531.58 Da
- Sequence: QEQLERALNSS
- Solubility: Soluble in water at ≥1 mg/mL
- Reconstitution: Add 1 mL bacteriostatic water per 5 mg; swirl gently
For in-vitro laboratory research use only. Not for human or veterinary use, consumption, or therapeutic application. No medical claims are made.